Stock GILD34 GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Gilead Sciences, Inc. Sao Paulo

Equities

GILD34

BRGILDBDR000

Pharmaceuticals

Market Closed - Sao Paulo
Other stock markets
 10:04:14 2024-07-11 am EDT 		5-day change 1st Jan Change
186.3 BRL +1.07% Intraday chart for Gilead Sciences, Inc. +2.29% -3.25%
Jul. 11 Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78 MT
Jul. 09 RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating MT

Business Summary

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Number of employees: 18,000

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Medicines
100.0 %
27,281 100.0 % 27,116 100.0 % -0.60%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
71.7 %
18,884 69.2 % 19,438 71.7 % +2.93%
Europe
15.9 %
4,469 16.4 % 4,310 15.9 % -3.56%
Other International
12.4 %
3,928 14.4 % 3,368 12.4 % -14.26%

Managers

Managers TitleAgeSince
Daniel O'Day CEO
 Chief Executive Officer 59 19-02-28
Andrew Dickinson DFI
 Director of Finance/CFO 54 15-12-31
Flavius Martin CTO
 Chief Tech/Sci/R&D Officer - 21-04-11
Merdad Parsey CTO
 Chief Tech/Sci/R&D Officer 61 19-10-31
Jacquie Ross IRC
 Investor Relations Contact - 20-12-31
Adam Levy PRN
 Corporate Officer/Principal - -
Stacey Ma PRN
 Corporate Officer/Principal 54 22-07-17
Tomas Cihlar PRN
 Corporate Officer/Principal 57 -
Jyoti Mehra HRO
 Human Resources Officer 48 17-10-31
Joydeep Ganguly PRN
 Corporate Officer/Principal - 18-12-31

Members of the board

Members of the board TitleAgeSince
Anthony Welters BRD
 Director/Board Member 69 20-10-16
Jacqueline Barton BRD
 Director/Board Member 71 17-12-31
Ted Love BRD
 Director/Board Member 65 Jan. 31
Harish M. Manwani BRD
 Director/Board Member 70 18-05-08
Javier Rodriguez BRD
 Director/Board Member 53 20-06-14
Daniel O'Day CEO
 Chief Executive Officer 59 19-02-28
Sandra Horning BRD
 Director/Board Member 75 20-01-27
Kelly Kramer BRD
 Director/Board Member 56 16-08-18
Jeffrey Bluestone BRD
 Director/Board Member 70 20-12-06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,245,853,209 1,244,423,111 ( 99.89 %) 0 99.89 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.209 %
114,732,575 9.209 % 7 872 M R$
BlackRock Advisors LLC
7.475 %
93,121,321 7.475 % 6 389 M R$
Capital Research & Management Co. (World Investors)
6.782 %
84,497,404 6.782 % 5 797 M R$
Capital Research & Management Co. (Global Investors)
4.916 %
61,246,366 4.916 % 4 202 M R$
STATE STREET CORPORATION
4.632 %
57,704,928 4.632 % 3 959 M R$
Dodge & Cox
2.662 %
33,167,487 2.662 % 2 276 M R$
ishares (DE) Invag Mit Teilgesellschaftsvermogen
2.170 %
27,030,078 2.170 % 1 855 M R$
Geode Capital Management LLC
2.115 %
26,349,355 2.115 % 1 808 M R$
Wellington Trust Co., NA
1.651 %
20,567,752 1.651 % 1 411 M R$
Eaton Vance Management
1.446 %
18,013,584 1.446 % 1 236 M R$
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000228 %
5,686 0.000228 % 195 954 R$
Bram Bradesco Asset Management S/A DTVM
0.000206 %
5,140 0.000206 % 177 137 R$

Holdings

NameEquities%Valuation
ARCUS BIOSCIENCES, INC.
34.67%
 31,532,781 34.67% 480,244,255 $
GALAPAGOS NV
25.35%
 16,707,477 25.35% 417,931,690 $
ARCELLX, INC.
12.56%
 6,720,803 12.56% 370,921,118 $
TANGO THERAPEUTICS, INC.
4.54%
 4,854,443 4.54% 41,651,121 $
KYVERNA THERAPEUTICS, INC.
9.57%
 4,126,119 9.57% 30,945,893 $
ASSEMBLY BIOSCIENCES, INC.
17.67%
 1,089,472 17.67% 14,947,556 $
ALLOVIR, INC.
14.47%
 16,635,286 14.47% 12,027,312 $
HOOKIPA PHARMA INC.
19.43%
 18,759,465 19.43% 11,105,603 $
LEAP THERAPEUTICS, INC.
13.90%
 5,319,148 13.90% 10,425,530 $
XILIO THERAPEUTICS, INC.
19.90%
 7,345,473 19.90% 6,956,163 $

Company contact information

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com
address Gilead Sciences, Inc.(GILD34)

Group companies

NameCategory and Sector
Gilead Sciences Ireland UC
Gilead Therapeutics A1 Unlimited Co.
Logo Gilead Therapeutics A1 Unlimited Co.

Gilead Therapeutics A1 Unlimited Co.

Pharmaceuticals: MajorHealth Technology

Part of Gilead Sciences, Inc., Gilead Therapeutics A1 Unlimited Co. is an Irish company that develops and manufactures pharmaceutical medicines. The company is located in Ireland.

Pharmaceuticals: Major

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.96 USD
Average target price
83.08 USD
Spread / Average Target
+18.75%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. GILD34 Stock
  5. Company Gilead Sciences, Inc.